Roche adds inhibitors to portfolio with Inflazome acquisition

Roche has acquired Inflazome, an Irish biotech developing orally available NLRP3 inflammasome inhibitors to address clinical unmet needs across a wide variety of inflammatory diseases

The deal sees Inflazome’s shareholders receive an upfront payment of €380 million ($449m) and are eligible to receive additional contingent payments to be made based on the achievement of certain predetermined milestones.

The acquisition gives Roche full rights to Inflazome’s entire portfolio which is composed of clinical and preclinical orally available small molecule NLRP3 inhibitors.

Roche intends to further develop NLRP3 inhibitors across a wide variety of indications with high unmet medical need.

“With Inflazome now part of the Roche organization, Inflazome’s pioneering molecules are well positioned to be developed quickly and effectively so they can help patients suffering from debilitating diseases,” said Matt Cooper, CEO of Inflazome.

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Related news